ThinkEquity Downgrades Nektar Therapeutics (NKTR) to Sell, Reaffirms $5 Price Target

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. BILL
5. ADI
6. MRK
7. MRNA
8. TJX
9. DE
10. LOW

January 17, 2012 7:56 AM EST
Get Alerts NKTR Hot Sheet
Price: $73.89 -2.88%

Rating Summary:
    20 Buy, 7 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
ThinkEquity downgraded shares of Nektar Therapeutics (NASDAQ: NKTR) to a Sell rating from its previous rating of Hold. The firm reaffirmed its price target of $5.00.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $6.72 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

ThinkEquity